Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia-Reference-Cited by-同舟云学术

Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia

Published:2013-07-16 Issue:19 Volume:119 Page:3555-3562
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Lipshultz Steven E.¹²,Lipsitz Stuart R.³,Kutok Jeffery L.⁴,Miller Tracie L.¹²,Colan Steven D.⁵,Neuberg Donna S.⁶,Stevenson Kristen E.⁶,Fleming Mark D.⁷,Sallan Stephen E.⁸,Franco Vivian I.¹,Henkel Jacqueline M.¹,Asselin Barbara L.⁹,Athale Uma H.¹⁰,Clavell Luis A.¹¹,Michon Bruno¹²,Laverdiere Caroline¹³,Larsen Eric¹⁴,Kelly Kara M.¹⁵,Silverman Lewis B.⁸

Affiliation:

1. Department of Pediatrics; University of Miami Miller School of Medicine; Miami Florida

2. Sylvester Comprehensive Cancer Center; University of Miami Miller School of Medicine; Miami Florida

3. Biostatistical Services; Center for Surgery and Public Health; Brigham and Women's Hospital; Boston Massachusetts

4. Department of Pathology; Brigham and Women's Hospital; Boston Massachusetts

5. Department of Cardiology; Boston Children's Hospital, Harvard Medical School; Boston Massachusetts

6. Department of Biostatistics and Computational Biology; Dana-Farber Cancer Institute; Boston Massachusetts

7. Department of Pathology; Boston Children's Hospital, Harvard Medical School; Boston Massachusetts

8. Department of Pediatric Oncology; Dana-Farber Cancer Institute and Division of Hematology-Oncology; Boston Children's Hospital; Boston Massachusetts

9. Department of Pediatrics; University of Rochester School of Medicine and Dentistry; Rochester New York

10. Department of Pediatrics; McMaster University; Hamilton Ontario Canada

11. Department of Pediatrics; San Jorge Children's Hospital; San Juan Puerto Rico

12. Department of Pediatric Hematology-Oncology, University Hospital of Quebec; Quebec City Quebec Canada

13. Department of Pediatrics; St. Justine Hospital; Montreal Quebec Canada

14. Division of Pediatric Hematology/Oncology; Maine Children's Cancer Program; Portland Maine

15. Division of Pediatric Hematology; Oncology; and Stem Cell Transplantation; Department of Pediatrics; Columbia University; New York New York

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28256/fullpdf

Reference40 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. Long-term survivors of childhood cancers in the United States;Mariotto;Cancer Epidemiol Biomarkers Prev,2009

3. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience;Krischer;J Clin Oncol,1997

4. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia;Lipshultz;J Clin Oncol,2005

5. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood;Lipshultz;N Engl J Med,1991

Cited by 134 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Iron metabolism in doxorubicin-induced cardiotoxicity: From mechanisms to therapies;The International Journal of Biochemistry & Cell Biology;2024-09

2. Ferroptosis: Latest evidence and perspectives on plant‐derived natural active compounds mitigating doxorubicin‐induced cardiotoxicity;Journal of Applied Toxicology;2024-07-18

3. Iron replacement in anthracycline-related cardiac dysfunction: fuel on the fire?;European Heart Journal;2024-07-10

4. Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci;The Pharmacogenomics Journal;2024-06-29

5. Molecular Mechanisms and Therapeutic Targeting of Ferroptosis in Doxorubicin-Induced Cardiotoxicity;JACC: Basic to Translational Science;2024-06